Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

ABSTRACT: The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.

DISEASE(S): Endometrial Cancer,Phase 1: Advanced Or Metastatic Cervical Cancer, Endometrial Cancer, Gastric Cancer, Hepatocellular Carcinoma, Melanoma (mucosal Or Cutaneous), Merkel Cell Carcinoma, Mesothelioma, Msi-h Colorectal Cancer, Non–small Cell Lung Cancer, Ovarian Cancer, Squamous Cell Carcinoma Of The Head And Neck (scchn), Small Cell Lung Cancer, Renal Cell Carcinoma, Triple-negative Breast Cancer, And Urothelial Carcinoma (or Others). phase 2: Advanced Or Metastatic Endometrial Cancer, Gastric Cancer, And Scchn,Cervical Cancer,Melanoma,Colorectal Cancer,Mesothelioma,Urothelial Carcinoma,Triple Negative Breast Cancer,Mesothelioma Malignant,Merkel Cell Carcinoma,Melanoma Malignant,Non-small Cell Lung Cancer (nsclc),Neoplasms,Ovarian Cancer,Squamous Cell Carcinoma Of Head And Neck,Advanced Malignancies,Renal Cell Carcinomas,Gastric Cancer,Metastatic Cancer,Hepatocellular Carcinoma

PROVIDER: 2242302 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

Project description:The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01949 when given in combination with immune therapies in participants with advanced or metastatic malignancies.

| 2251135 | ecrin-mdr-crc

Natural Killer Cell Therapies for Hematologic Malignancies

Project description:Natural Killer Cell Therapies for Hematologic Malignancies

| PRJNA776383 | ENA

Natural Killer Cell Therapies for Hematologic Malignancies

Project description:Natural Killer Cell Therapies for Hematologic Malignancies

| PRJNA776384 | ENA

Allogenic and Autologous anti-CD7 CAR-T cell Therapies in Relapsed or Refractory T-Cell Malignancies

Project description:Chimeric antigen receptor-T (CAR-T) therapy remains to be investigated in T-cell malignancies. CD7 is an ideal target for T-cell malignancies but is also expressed on normal T cells, which may cause CAR-T cell fratricide. Donor-derived anti-CD7 CAR-T cells using endoplasmic reticulum retention have shown efficacy in patients with T-cell acute lymphoblastic leukemia (ALL). Here we launched a phase I trial to explore differences between autologous and allogeneic anti-CD7 CAR-T therapies in T-cell ALL and lymphoma. Ten patients were treated and 5 received autologous CAR-T therapies. No dose-limiting toxicity or neurotoxicity was observed. Grade 1-2 cytokine release syndrome occurred in 7 patients, and grade 3 in 1 patient. Grade 1-2 graft-versus-host diseases were observed in 2 patients. Seven patients had bone marrow infiltration, and 100% of them achieved complete remission with negative minimal residual disease within one month. Two-fifths of patients achieved extramedullary or extranodular remission. The median follow-up was 6 (range, 2.7- 14) months and bridging transplantation was not administrated. Patients treated with allogeneic CAR-T cells had higher remission rate, less recurrence and more durable CAR-T survival than those receiving autologous products. Allogeneic CAR-T cells appeared to be a better option for patients with T-cell malignancies.

2023-03-25 | GSE227828 | GEO

Spatial coupling of microbes and immune cells in solid malignancies.

Project description:Spatial coupling of microbes and immune cells in solid malignancies.

| PRJNA882182 | ENA

Spatial coupling of microbes and immune cells in solid malignancies

Project description:Spatial coupling of microbes and immune cells in solid malignancies

| PRJNA655408 | ENA

Allogenic and Autologous anti-CD7 CAR-T cell Therapies in Relapsed or Refractory T-Cell Malignancies

Project description:Allogenic and Autologous anti-CD7 CAR-T cell Therapies in Relapsed or Refractory T-Cell Malignancies

| PRJNA947149 | ENA

Combined loss of Tet1 and Tet2 promotes B-cell, but not myeloid malignancies in mice

Project description:TET1/2/3 are methylcytosine dioxygenases regulating cytosine hydroxymethylation in the genome. Tet1 and Tet2 are abundantly expressed in HSC/HPCs and implicated in the pathogenesis of hematological malignancies. Tet2-deletion in mice causes myeloid malignancies, while Tet1-null mice develop B-cell lymphoma after an extended period of latency. Interestingly, TET1 and TET2 were often concomitantly down-regulated in acute B-lymphocytic leukemia. Here, we investigated the overlapping and non-redundant functions of Tet1/Tet2 in HSC maintenance and development of hematological malignancies using Tet1/2 double knockout (DKO) mice. DKO and Tet2-/- HSC/HPCs had overlapping and unique 5hmC and 5mC profiles and behaved differently. DKO mice exhibited strikingly decreased incidence and delayed onset of myeloid malignancies compared to Tet2-/- mice and in contrast developed lethal B-cell malignancies. Transcriptome analysis of DKO tumors revealed expression changes in many genes dysregulated in human B-cell malignancies, such as LMO2, BCL6 and MYC. These results highlight the critical roles of TET1 or TET2 individually and their cross-talks in the pathogenesis of hematological malignancies. Given the role of Tet proteins in 5mC oxidation, we employed a previously established chemical labeling and affinity purification method coupled with high-throughput sequencing (hMe-Seal) to profile the genome-wide distribution of 5hmC, as well as methylated DNA immunoprecipitation (MeDIP) coupled with high-throughput sequencing (MeDIP-seq) to profile 5mC using BM LK cells purified from young WT, Tet2-/- and DKO mice (6-10 wks old).

2015-11-12 | E-GEOD-73611 | biostudies-arrayexpress

Spatial coupling of microbes and immune cells in solid malignancies [LCM_stroma_epithelium]

Project description:Spatial coupling of microbes and immune cells in solid malignancies [LCM_stroma_epithelium]

| PRJNA655411 | ENA

Spatial coupling of microbes and immune cells in solid malignancies [Whole_slides]

Project description:Spatial coupling of microbes and immune cells in solid malignancies [Whole_slides]

| PRJNA655410 | ENA